CytoDyn (OTCQB: CYDY), a biotechnology company developing a
novel humanized CCR5 monoclonal antibody for multiple therapeutic indications,
this morning announced that Nader Pourhassan, Ph.D., president and CEO and
Richard Pestell, M.D., Ph.D., F.A.C.P., M.B.A., Chief Medical Officer, will
present at two investment conferences during the month of December. First,
taking place on Tuesday, December 4, 2018 at 1:30 p.m. ET, the company will
present at the 11th Annual LD Micro Main Event at the Luxe Sunset Boulevard
Hotel in Los Angeles. On Thursday, December 13, 2018, the company will present
at the Singular Research “Best of the Uncovered” – Small Cap 13th Annual
Conference 2018 being held in San Francisco. A live webcast and replay of the
company’s presentation at the LD Micro Main Event will be available on the
investors section of CytoDyn’s website.
To view the full press release, visit http://ibn.fm/TlqqP
About CytoDyn
CytoDyn is a biotechnology company developing innovative
treatments for multiple therapeutic indications based on PRO 140 (leronlimab),
a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a
key role in the ability of HIV to enter and infect healthy T-cells. The
CCR5 receptor is also implicated in tumor metastasis and in immune-mediated
illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has
successfully completed a Phase 3 pivotal trial with PRO 140 in combination with
standard anti-retroviral therapies in HIV-infected treatment-experienced
patients. The Company plans to seek FDA approval for PRO 140 in combination
therapy and plans to complete the filing of a Biological License Application
(BLA) in the first quarter of 2019 for that indication. CytoDyn is also
conducting a Phase 3 investigative trial with PRO 140 as a once-weekly
monotherapy for HIV-infected patients, and plans to initiate a
registration-directed study of PRO 140 monotherapy indication, which if
successful, could support a label extension. Clinical results to date from
multiple trials have shown that PRO 140 can significantly reduce viral burden
in people infected with HIV with no reported drug-related serious adverse
events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated
that PRO 140 monotherapy can prevent viral escape in HIV-infected patients,
with some patients on PRO 140 monotherapy remaining virally suppressed for more
than four years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140
for the prevention of GvHD and expects to initiate clinical trials with PRO 140
in metastatic triple-negative breast cancer in 2018. For more information,
visit the company’s website at www.CytoDyn.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is committed
to connecting subscribers with companies that have huge potential to succeed in
the short and long-term future. It is part of our mission statement to help the
investment community discover emerging companies that offer excellent growth
potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
QualityStocks has received compensation from CytoDyn Inc.
for providing certain investor relations, marketing and social media services,
including the preparation of this report, and expects to receive additional
compensation for such services in the future. This compensation includes a
monthly program fee.
No comments:
Post a Comment